Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma

• Teiji Kuzuya,

  Affiliation Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan

  ⨯
• Masatoshi Ishigami ,

  * E-mail: masaishi@med.nagoya-u.ac.jp

  Affiliation Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan

  ⨯
• Yoji Ishizu,

  Affiliation Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan

  ⨯
• Takashi Honda,

  Affiliation Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan

  ⨯
• Kazuhiko Hayashi,

  Affiliation Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan

  ⨯
• Yoshiaki Katano,

  Affiliation Department of Gastroenterology, Banbuntane Hotokukai Hospital, Fujita Health University, School of Medicine, Nagoya, Japan

  ⨯
• Yoshiki Hirooka,

  Affiliation Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan

  ⨯
• Tetsuya Ishikawa,

  Affiliation Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan

  ⨯
• Isao Nakano,

  Affiliation Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan

  ⨯
• Hidemi Goto

  Affiliation Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan

  ⨯